Published in Nat Med on March 01, 1999
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci U S A (2007) 3.54
The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J (2011) 2.97
Transcriptional programs activated by exposure of human prostate cancer cells to androgen. Genome Biol (2002) 2.87
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 2.34
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res (2008) 2.29
The role of HER2 in cancer therapy and targeted drug delivery. J Control Release (2010) 1.88
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Glucocorticoid receptor phosphorylation differentially affects target gene expression. Mol Endocrinol (2008) 1.81
The evolving biology and treatment of prostate cancer. J Clin Invest (2007) 1.81
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell (2009) 1.77
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1. Proc Natl Acad Sci U S A (2006) 1.75
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer (2008) 1.70
Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 1.65
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol (1999) 1.56
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol (2002) 1.55
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol (2001) 1.46
KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and surviving in prostate cancer models. BMC Cancer (2015) 1.44
Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res (2008) 1.39
Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol (2010) 1.35
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res (2009) 1.34
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res (2009) 1.32
Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res (2011) 1.32
Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression. Proc Natl Acad Sci U S A (2012) 1.32
Modulating metastasis by a lymphangiogenic switch in prostate cancer. Int J Cancer (2007) 1.30
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci U S A (2007) 1.27
Androgen action and metabolism in prostate cancer. Mol Cell Endocrinol (2012) 1.25
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic Acids Res (2007) 1.22
Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clin Cancer Res (2010) 1.22
The androgen receptor can signal through Wnt/beta-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens. BMC Cell Biol (2008) 1.21
The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem (2011) 1.20
miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem (2009) 1.19
The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol (2005) 1.19
Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol (2012) 1.19
Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci (2013) 1.16
Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res (2010) 1.16
Specificity and heregulin regulation of Ebp1 (ErbB3 binding protein 1) mediated repression of androgen receptor signalling. Br J Cancer (2005) 1.15
A novel steroid receptor co-activator protein (SRAP) as an alternative form of steroid receptor RNA-activator gene: expression in prostate cancer cells and enhancement of androgen receptor activity. Biochem J (2003) 1.15
Chromatin accessibility reveals insights into androgen receptor activation and transcriptional specificity. Genome Biol (2012) 1.15
Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A (2005) 1.14
Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog (2007) 1.14
Simian virus 40 small t antigen mediates conformation-dependent transfer of protein phosphatase 2A onto the androgen receptor. Mol Cell Biol (2005) 1.13
The NF-kappaB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches? World J Urol (2007) 1.13
Soy isoflavones and prostate cancer: a review of molecular mechanisms. J Steroid Biochem Mol Biol (2013) 1.13
Shepherding AKT and androgen receptor by Ack1 tyrosine kinase. J Cell Physiol (2010) 1.13
Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol (2005) 1.12
Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res (2010) 1.11
Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer. FASEB J (2010) 1.11
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications. Mol Cancer Ther (2011) 1.10
Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate (2009) 1.08
Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer (2004) 1.08
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2011) 1.08
Evolution of androgen receptor targeted therapy for advanced prostate cancer. Nat Rev Clin Oncol (2014) 1.08
Androgen receptor expression in prostate cancer cells is suppressed by activation of epidermal growth factor receptor and ErbB2. Cancer Res (2009) 1.07
Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol (2008) 1.07
Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol (2002) 1.06
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr Relat Cancer (2012) 1.06
Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology (2011) 1.06
Kinases and protein phosphorylation as regulators of steroid hormone action. Nucl Recept Signal (2007) 1.04
Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Mol Endocrinol (2007) 1.04
Mouse models of prostate cancer. Prostate Cancer (2011) 1.04
Human prostatic acid phosphatase, an authentic tyrosine phosphatase, dephosphorylates ErbB-2 and regulates prostate cancer cell growth. J Biol Chem (2010) 1.03
Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol (2008) 1.03
β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest (2013) 1.03
Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer (2010) 1.03
EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol Cancer Ther (2008) 1.03
Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol Imaging (2005) 1.01
Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem (2009) 1.01
Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. Proc Natl Acad Sci U S A (2003) 1.01
Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res (2009) 1.00
CXC receptor-1 silencing inhibits androgen-independent prostate cancer. Cancer Res (2009) 1.00
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer (2007) 1.00
Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One (2013) 1.00
Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab (2010) 1.00
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res (2006) 0.99
Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer (2007) 0.99
Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) (2010) 0.98
Targeting tyrosine kinases and autophagy in prostate cancer. Horm Cancer (2010) 0.98
A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia (2011) 0.97
A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49. Am J Pathol (2002) 0.97
Oncogenic activation of androgen receptor. Urol Oncol (2008) 0.97
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol (2007) 0.96
Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for prostate cancer. Carcinogenesis (2010) 0.95
Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. Am J Pathol (2001) 0.95
The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function. Am J Pathol (2003) 0.95
Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect (2007) 0.95
Analysis of the molecular networks in androgen dependent and independent prostate cancer revealed fragile and robust subsystems. PLoS One (2010) 0.94
Mechanisms of acquired androgen independence during arsenic-induced malignant transformation of human prostate epithelial cells. Environ Health Perspect (2006) 0.94
Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. Int J Cancer (2008) 0.94
Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases. Am J Pathol (2009) 0.94
Insulin-like growth factor 1 stimulation of androgen receptor activity requires β(1A) integrins. J Cell Physiol (2012) 0.93
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med (2001) 24.51
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (2001) 20.30
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med (2001) 11.88
Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 6.99
DNA recognition by GAL4: structure of a protein-DNA complex. Nature (1992) 5.60
A cytoplasmic inhibitor of the JNK signal transduction pathway. Science (1997) 4.56
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A (1998) 4.18
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA (1993) 3.09
How different eukaryotic transcriptional activators can cooperate promiscuously. Nature (1990) 2.91
Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2. Proc Natl Acad Sci U S A (2000) 2.65
Polymerase II promoter activation: closed complex formation and ATP-driven start site opening. Science (1992) 2.42
Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res (1999) 2.38
The rational clinical examination. Does this patient have strep throat? JAMA (2000) 2.30
A general mechanism for transcriptional synergy by eukaryotic activators. Nature (1995) 2.29
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene (1996) 2.17
Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A (2007) 2.11
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation. Proc Natl Acad Sci U S A (1995) 2.10
Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. J Clin Endocrinol Metab (2000) 2.09
Activation of yeast polymerase II transcription by herpesvirus VP16 and GAL4 derivatives in vitro. Mol Cell Biol (1989) 2.06
Expression of enhanced levels of small RNA polymerase III transcripts encoded by the B2 repeats in simian virus 40-transformed mouse cells. Nature (1985) 1.98
Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A (1979) 1.96
Predictors of large esophageal varices in patients with cirrhosis. Am J Gastroenterol (1999) 1.93
The acidic activator GAL4-AH can stimulate polymerase II transcription by promoting assembly of a closed complex requiring TFIID and TFIIA. Genes Dev (1992) 1.89
Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A (2001) 1.85
Recruitment of the putative transcription-repair coupling factor CSB/ERCC6 to RNA polymerase II elongation complexes. Mol Cell Biol (1997) 1.83
The effects of intracuff lidocaine on endotracheal-tube-induced emergence phenomena after general anesthesia. Anesth Analg (2000) 1.77
The requirement for the basal transcription factor IIE is determined by the helical stability of promoter DNA. EMBO J (1995) 1.77
Assembly of the isomerized TFIIA--TFIID--TATA ternary complex is necessary and sufficient for gene activation. Genes Dev (1996) 1.76
Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol (2001) 1.73
Yeast HMG proteins NHP6A/B potentiate promoter-specific transcriptional activation in vivo and assembly of preinitiation complexes in vitro. Genes Dev (1996) 1.66
Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination. Clin Infect Dis (1999) 1.59
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol (1999) 1.56
Differential complementation of Bcr-Abl point mutants with c-Myc. Science (1994) 1.52
A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. EMBO J (1992) 1.51
Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene (2001) 1.48
Patient response to laryngeal mask insertion after induction of anaesthesia with propofol or thiopentone. Can J Anaesth (1993) 1.47
In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res (2001) 1.46
Mechanism for specificity by HMG-1 in enhanceosome assembly. Mol Cell Biol (2000) 1.44
Reduction of severity of pruritus after elective caesarean section under spinal anaesthesia with subarachnoid morphine: a randomised comparison of prophylactic granisetron and ondansetron. Int J Obstet Anesth (2009) 1.41
Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series. Int J Gynecol Cancer (2007) 1.39
Some reasons for the lack of progress in the treatment of acute myelogenous leukemia: a review of three consecutive trials of the treatment of poor prognosis patients. Leuk Res (1991) 1.38
Brucella abortus genes identified following constitutive growth and macrophage infection. Infect Immun (2001) 1.34
Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther (2001) 1.33
The ZEBRA activation domain: modular organization and mechanism of action. Mol Cell Biol (1993) 1.33
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem (1996) 1.33
Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem (1999) 1.32
A heteroduplex template circumvents the energetic requirement for ATP during activated transcription by RNA polymerase II. J Biol Chem (1994) 1.31
The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf. Mol Cell Biol (2000) 1.31
Down-Regulation of prostate-specific antigen expression by ligands for peroxisome proliferator-activated receptor gamma in human prostate cancer. Cancer Res (2000) 1.30
Arachnoid cyst and associated subdural hematoma. Observations on conventional roentgenographic and computerized tomographic diagnosis. Arch Neurol (1978) 1.27
Modulating the potency of an activator in a yeast in vitro transcription system. Mol Cell Biol (1994) 1.27
The role of activators in assembly of RNA polymerase II transcription complexes. Curr Opin Genet Dev (1994) 1.25
Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage (1993) 1.22
Graphical search for two-stage designs for phase II clinical trials. Control Clin Trials (2001) 1.20
Signal transduction by wild-type and leukemogenic Abl proteins. Biochim Biophys Acta (1997) 1.20
Changes in performance, muscle metabolites, enzymes and fibre types after short sprint training. Eur J Appl Physiol Occup Physiol (1998) 1.18
Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program (2001) 1.16
Correlation between exchange bias and pinned interfacial spins. Phys Rev Lett (2003) 1.16
p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase. Oncogene (1995) 1.15
Markers of low level arsenic exposure for evaluating human cancer risks in a US population. Int J Occup Med Environ Health (2001) 1.13
Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes Cancer (2001) 1.11
Compensatory energetic relationships between upstream activators and the RNA polymerase II general transcription machinery. J Biol Chem (1998) 1.09
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells. Mol Cell Biol (1998) 1.09
The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer (2004) 1.06
Muscle metabolism during sprint exercise in man: influence of sprint training. J Sci Med Sport (2004) 1.06
Protease footprinting reveals a surface on transcription factor TFIIB that serves as an interface for activators and coactivators. Proc Natl Acad Sci U S A (1995) 1.03
Transcription factor IIA derepresses TATA-binding protein (TBP)-associated factor inhibition of TBP-DNA binding. J Biol Chem (1998) 1.02
Multiple layers of cooperativity regulate enhanceosome-responsive RNA polymerase II transcription complex assembly. Mol Cell Biol (1999) 1.02
Activity of aortic chemoreceptors in the anaesthetized rat. J Physiol (1999) 1.01
A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis (1986) 1.01
Effects of positive airway pressure on upper airway dilator muscle activity and ventilatory timing. J Appl Physiol (1985) (1996) 1.00
Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer. Clin Cancer Res (2001) 0.99
Association of central obesity with early Carotid intima-media thickening is independent of that from other risk factors. Int J Obes (Lond) (2008) 0.98
T lymphocyte mediated protection against facultative intracellular bacteria. Vet Immunol Immunopathol (1996) 0.97
Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res (2005) 0.97
Bone mass and structure at the hip in men and women over the age of 60 years. Osteoporos Int (1998) 0.95
Biochemical mechanism of transcriptional activation by GAL4-VP16. Methods Enzymol (1996) 0.95
Central neurocytoma: a correlative clinicopathologic and radiologic analysis. Surg Neurol (1998) 0.95
Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging. Gene Ther (2008) 0.92
Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev (1999) 0.92
Cancer patients' concerns regarding access to cancer care: perceived impact of waiting times along the diagnosis and treatment journey. Eur J Cancer Care (Engl) (2011) 0.91
A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer (2002) 0.90
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency. Proc Natl Acad Sci U S A (2000) 0.89
The sinking bullet. Neurosurgery (1992) 0.88
Effect of diet on serum accumulation and renal excretion of aryl acids and secretory activity in normal and uremic man. Am J Clin Nutr (1975) 0.88
A near-native state on the slow refolding pathway of hen lysozyme. Protein Sci (1999) 0.87
Rapid domain wall motion in permalloy nanowires excited by a spin-polarized current applied perpendicular to the nanowire. Phys Rev Lett (2010) 0.87
A comparison of the insertion characteristics of the laryngeal tube and the laryngeal mask airway: a study of the ED50 propofol requirements. Anaesthesia (2006) 0.87
Folding of apocytochrome c in lipid micelles: formation of alpha-helix precedes membrane insertion. Biochemistry (1999) 0.86
Oxytocin and vasopressin expression in the ovine testis and epididymis: changes with the onset of spermatogenesis. Biol Reprod (2000) 0.86
Research on resistance to cancer drug Gleevec. Science (2001) 0.86
Identification of a pseudogene that can masquerade as a mutant allele of the PTEN/MMAC1 tumor suppressor gene. J Natl Cancer Inst (1998) 0.85
Direct repair vs. overlapping sphincter repair: a randomized, controlled trial. Dis Colon Rectum (2003) 0.85
A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol (1997) 0.85
Educational interventions for migrant South Asians with Type 2 diabetes: a systematic review. Diabet Med (2008) 0.84
Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer. Curr Opin Investig Drugs (2001) 0.84